drugset
drugset / Trial / NCT05644600

A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.

NCT05644600 ↗

Phase 1 Terminated 18 enrolled AstraZeneca Parexel · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The study is intended to quantify the effect of co-administration and staggered dosing of AZD5055 and nintedanib on exposures of nintedanib in healthy participants.

Timeline

Start
2023-05-26
Primary completion
2023-07-17
Completion
2023-07-17

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5055 Unknown — Oral
Subject Nintedanib Small molecule — Oral

Indications

No indication recorded.